LIPIDOLIV

Role of the transcription factor ChREBP and its associated proteins in the development and progression of NAFLD

Coordinatore	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	France [FR]
Totale costo	1˙500˙000 €
EC contributo	1˙500˙000 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2013-StG
Funding Scheme	ERC-SG
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-02-01   -   2019-01-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)  Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Dr. Nome: "Renaud, Stéphane" Cognome: Dentin Email: send email Telefono: 33153732720 Fax: 33144412421	FR (PARIS)	hostInstitution	1˙500˙000.00
2	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)  Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Mrs. Nome: Lyddie Cognome: Laaland Email: send email Telefono: +33 1 40 78 49 35 Fax: +33 1 40 78 49 98	FR (PARIS)	hostInstitution	1˙500˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Changes in lifestyle have resulted in a dramatic epidemic of type 2 diabetes and obesity. Among associated complications, Nonalcoholic Fatty Liver Disease (NAFLD) is emerging as the most common chronic liver disease and is gaining increasing recognition as a component of the epidemic of obesity. NAFLD is generally asymptomatic, although a minority of patients may present progressive liver injury with complications of Nonalcoholic steatohepatitis (NASH), cirrhosis and HCC. Excessive accumulation of fatty acids (FA) stored as triglycerides (TGs) in hepatocytes is the hallmark of NAFLD, which is strongly associated with insulin resistance (IR). However, despite the existing correlation between fatty liver and insulin resistance, it remains unclear whether insulin resistance causes the excessive accumulation of TG in the liver, or whether the increase in TG itself or other lipid intermediates such as diacylglycerols (DAG) and/or ceramides may trigger the development of hepatic or systemic insulin resistance. While some studies support the concept that intrahepatic accumulation of lipids precedes insulin resistance, others suggest that hepatic TG may in fact protect the liver from lipotoxicity by buffering the accumulation of FA. Such discrepancy might be explained since different pools of lipids exist within cells and only certain pools regulate insulin signaling. Consistent with such hypothesis, recent results by our group strongly support that specific FA species may influence hepatic TG storage, insulin signaling and/or inflammation. Therefore, the global aim of our proposal is to better understand the regulation of hepatic fatty acid synthesis and partitioning in addition to its impact on the detailed lipid profile. Using state-of-art technology and key genetically modified mouse models combined with original nutritional approaches and lipidomic analysis, our project aims at providing new information on the molecular basis of the pathogenesis of NAFLD.'